Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281124 · ClinicalTrials.gov registry record · Phase 2
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01281124: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01281124 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01281124, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- DRUG Azacitidine
- OTHER Diagnostic Laboratory Biomarker Analysis
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-01-12 |
| Est. Completion | 2012-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281124
The ClinicalTrials.gov registry entry for NCT01281124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT01281124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281124 about?
NCT01281124 is a clinical study titled "Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer". This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping ...
What is the current status of trial NCT01281124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2011-01-12. Estimated completion is 2012-09-12.
What interventions are being tested in trial NCT01281124?
The interventions under investigation include: Azacitidine (DRUG), Diagnostic Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01281124?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.